Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Avapritinib for advanced systemic mastocytosis
Jason Gotlib, Andreas Reiter, Daniel J. DeAngelo
Blood (2022) Vol. 140, Iss. 15, pp. 1667-1673
Closed Access | Times Cited: 27

Showing 1-25 of 27 citing articles:

Pyrazole: an Emerging Privileged Scaffold in Drug Discovery
Mohammad A. Alam
Future Medicinal Chemistry (2023) Vol. 15, Iss. 21, pp. 2011-2023
Open Access | Times Cited: 22
World Health Organization Classification and Diagnosis of Mastocytosis
Peter Valent, Karl Sotlar, Hans‐Peter Horny, et al.
Immunology and Allergy Clinics of North America (2023) Vol. 43, Iss. 4, pp. 627-649
Closed Access | Times Cited: 11
Analysis of postmarketing neuropsychiatric adverse events of avapritinib based on the FDA adverse event reporting system
Wei Mao, Junyan Jiang, Yanping Xia, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
The Impact of Mast Cells on the Anatomy, Cellular Communication, and Molecular Immune Network of Lymph Nodes
Daniel Elieh Ali Komi, Marcus Maurer, Frank Siebenhaar
Clinical Reviews in Allergy & Immunology (2025) Vol. 68, Iss. 1
Open Access
Mastocytosis
Cem Akin, Michel Arock, Melody C. Carter, et al.
Nature Reviews Disease Primers (2025) Vol. 11, Iss. 1
Closed Access
Siglecs as potential targets of therapy in human mast cell- and/or eosinophil-associated diseases
Jeremy A. O’Sullivan, Bradford A. Youngblood, Robert P. Schleimer, et al.
Seminars in Immunology (2023) Vol. 69, pp. 101799-101799
Open Access | Times Cited: 10
Avapritinib is effective for treatment of minimal residual disease in acute myeloid leukemia with t (8;21) and kit mutation failing to immunotherapy after allogeneic hematopoietic stem cell transplantation
Jun Kong, Fengmei Zheng, Zhidong Wang, et al.
Bone Marrow Transplantation (2023) Vol. 58, Iss. 7, pp. 777-783
Closed Access | Times Cited: 9
Disease Spectrum of Anaphylaxis Disorders
David González‐de‐Olano, W. Cain, Jonathan A. Bernstein, et al.
The Journal of Allergy and Clinical Immunology In Practice (2023) Vol. 11, Iss. 7, pp. 1989-1996
Closed Access | Times Cited: 9
Is Autophagy Targeting a Valid Adjuvant Strategy in Conjunction with Tyrosine Kinase Inhibitors?
Ahmed M. Elshazly, Jingwen Xu, Nebras Y. Melhem, et al.
Cancers (2024) Vol. 16, Iss. 17, pp. 2989-2989
Open Access | Times Cited: 3
A post‐marketing pharmacovigilance study of avapritinib: Adverse event data mining and analysis based on the United States Food and Drug Administration Adverse Event Reporting System database
Li Rong, Mengyuan Xie, Manxue Jiang, et al.
British Journal of Clinical Pharmacology (2023) Vol. 90, Iss. 8, pp. 1816-1826
Closed Access | Times Cited: 9
MITF Downregulation Induces Death in Human Mast Cell Leukemia Cells and Impairs IgE-Dependent Degranulation
Elizabeth Proaño-Pérez, Laia Ollé, Yanru Guo, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 4, pp. 3515-3515
Open Access | Times Cited: 8
KIT Mutations and Other Genetic Defects in Mastocytosis
Yannick Chantran, Peter Valent, Michel Arock
Immunology and Allergy Clinics of North America (2023) Vol. 43, Iss. 4, pp. 651-664
Open Access | Times Cited: 8
TKI Treatment Sequencing in Advanced Gastrointestinal Stromal Tumors
Homma M. Khosroyani, Lillian R. Klug, Michael C. Heinrich
Drugs (2023) Vol. 83, Iss. 1, pp. 55-73
Open Access | Times Cited: 7
Systemic mastocytosis: 2023 update on diagnosis and management in adults
Alessandro Nanni Costa, Emilia Scalzulli, Ida Carmosino, et al.
Expert Opinion on Emerging Drugs (2023) Vol. 28, Iss. 3, pp. 153-165
Closed Access | Times Cited: 7
Can molecular patterns help to classify overlapping entities in myeloid neoplasms?
Gregor Hoermann, Joseph D. Khoury
Histopathology (2024)
Open Access | Times Cited: 2
Advanced Systemic Mastocytosis with associated haematological neoplasm: Treatment with avapritinib can facilitate successful bridge to allogeneic haematopoietic cell transplant
Priya Sriskandarajah, Donal P. McLornan, Clare Oni, et al.
Current Research in Translational Medicine (2023) Vol. 71, Iss. 3, pp. 103398-103398
Closed Access | Times Cited: 6
European Competence Network on Mastocytosis (ECNM): 20-Year Jubilee, Updates, and Future Perspectives
Peter Valent, Karin Hartmann, Patrizia Bonadonna, et al.
The Journal of Allergy and Clinical Immunology In Practice (2023) Vol. 11, Iss. 6, pp. 1706-1717
Open Access | Times Cited: 5
Updates in diagnosis and management of paediatric mastocytosis
Rasa Tiano, Ifat Z Krase, Keith Sacco
Current Opinion in Allergy and Clinical Immunology (2022) Vol. 23, Iss. 2, pp. 158-163
Closed Access | Times Cited: 8
Clearance of bone marrow mast cells after hypomethylating agent and venetoclax for systemic mastocytosis associated with myeloid neoplasia
Hoda Pourhassan, Young Kim, Vinod Pullarkat
European Journal Of Haematology (2022) Vol. 110, Iss. 2, pp. 213-216
Open Access | Times Cited: 5
Mastocytosis—a frequently unrecognized disease
Melba Muñoz, Frank Siebenhaar
best practice onkologie (2024) Vol. 19, Iss. 5, pp. 206-217
Closed Access
Nouveaux critères diagnostiques des mastocytoses : des progrès mais encore des interrogations
Michel Arock
Bulletin de l Académie Nationale de Médecine (2024) Vol. 208, Iss. 6, pp. 810-823
Closed Access
Utility of KIT Mutations in Myeloid Neoplasms Without Documented Systemic Mastocytosis to Detect Hidden Mast Cells in Bone Marrow
Do H. Kim, Fuli Jia, Keyur P. Patel, et al.
Clinical Lymphoma Myeloma & Leukemia (2024) Vol. 24, Iss. 11, pp. e878-e882
Open Access
Diarrhea-predominant irritable bowel syndrome as a masquerade for systemic mastocytosis: review article and illustrating case report
Mansour Aljabry
Archives of Medical Science (2024) Vol. 20, Iss. 4, pp. 1063-1068
Open Access
The clinical experience of compassionate use program for avapritinib: implications for drug positioning in the therapeutic scenario of systemic mastocytosis
Francesco Mannelli, Francesca Crupi, Roberta Zanotti, et al.
Therapeutic Advances in Hematology (2023) Vol. 14
Open Access | Times Cited: 1
Mastocytosis—a frequently unrecognized disease
Melba Muñoz, Frank Siebenhaar
Deleted Journal (2023)
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top